meningococcal group A, C, Y and W-135 conjugate vaccine

The Group ACYW135 Meningococcal Conjugate Vaccine (MCV4) developed by Ningbo Rong'an Biological Pharmaceutical (a subsidiary of AIM Vaccine) is a quadrivalent vaccine designed to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. Unlike traditional polysaccharide vaccines, this conjugate vaccine chemically links the capsular polysaccharides of the four serogroups to a carrier protein. This conjugation technology converts the T-cell independent polysaccharides into T-cell dependent antigens, which induces a more robust immune response, particularly in infants and young children, and promotes long-term immunological memory. The vaccine is administered via intramuscular injection and has received regulatory approval in China.

Other names

Group ACYW135 meningococcal conjugate vaccineACYW135 meningococcal conjugate vaccineACYW-135 meningococcal conjugate vaccineACYW 135 meningococcal conjugate vaccineQuadrivalent meningococcal conjugate vaccine